Adicet Bio (LSE:0HX7) - Cours de l'action, nouvelles et analyse

0HX7 Aperçu des actions

0HX7 analyse fondamentale
Score flocon de neige
Évaluation	4/6
Croissance future	2/6
Performances passées	0/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Se négocie à 95.8% en dessous de notre estimation de sa juste valeur

Les revenus devraient augmenter 79.7% par an

Analyse des risques

Réalise moins d'un million de dollars de revenus ( $0 )

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

Cours de l'action très volatil au cours des 3 derniers mois

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

+ 1 plus de risques

Adicet Bio, Inc. Concurrents

e-therapeutics

AIM:ETX

UK£52.6m

OptiBiotix Health

AIM:OPTI

UK£12.5m

Tissue Regenix Group

AIM:TRX

UK£40.6m

PureTech Health

LSE:PRTC

UK£408.0m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Adicet Bio
Historique des cours de bourse
Prix actuel de l'action	US$0.91
Plus haut sur 52 semaines	US$3.74
Plus bas sur 52 semaines	US$0.91
Bêta	1.7
1Variation sur 1 mois	-35.25%
Variation sur 3 mois	-39.05%
Variation sur 1 an	-19.35%
3Variation sur 3 ans	-90.35%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-93.32%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	0HX7	GB Biotechs	GB Marché
7D	-7.9%	1.5%	2.2%
1Y	-19.4%	-17.9%	8.8%

Rendement vs Industrie: 0HX7 a sous-performé le secteur UK Biotechs qui a rapporté -17.9 % au cours de l'année écoulée.

Rendement vs marché: 0HX7 a sous-performé le marché UK qui a rapporté 8.8 % au cours de l'année écoulée.

Volatilité des prix

Is 0HX7's price volatile compared to industry and market?
0HX7 volatility
0HX7 Average Weekly Movement	11.5%
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Cours de l'action stable: Le cours de l'action de 0HX7 a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de 0HX7 ( 11% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de UK.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2014	143	Chen Schor	www.adicetbio.com

Adicet Bio, Inc. est une société de biotechnologie en phase clinique qui découvre et développe des thérapies à base de cellules T gamma delta allogéniques pour les maladies auto-immunes et le cancer. La société propose des cellules T gamma delta conçues avec des récepteurs antigéniques chimériques (CAR) pour faciliter une activité durable chez les patients. Son principal produit candidat est l'ADI-001, une thérapie par cellules T gamma delta allogéniques exprimant un CAR ciblant le CD20, qui est en essai clinique de phase I pour le traitement des maladies auto-immunes et du lymphome non hodgkinien agressif à cellules B récidivant ou réfractaire.

Adicet Bio, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Adicet Bio se comparent-ils à sa capitalisation boursière ?
0HX7 statistiques fondamentales
Capitalisation boursière	US$74.16m
Bénéfices(TTM)	-US$117.88m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-0.6x

Ratio P/E

Le site 0HX7 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
0HX7 compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$0
Marge brute	US$0
Autres dépenses	US$117.88m
Les revenus	-US$117.88m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.43
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de 0HX7?

Voir les performances historiques et les comparaisons

0HX7 Aperçu des actions

Récompenses

Analyse des risques

Adicet Bio, Inc. Concurrents

AIM:ETX

UK£52.6m

AIM:OPTI

UK£12.5m

AIM:TRX

UK£40.6m

LSE:PRTC

UK£408.0m

Historique des prix et performances

Nouvelles et mises à jour récentes

Adicet Bio, Inc. Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

New minor risk - Market cap size

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Recent updates

Adicet Bio, Inc. Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

New minor risk - Market cap size

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

New minor risk - Market cap size

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Full year 2022 earnings released: US$1.70 loss per share (vs US$2.00 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

High number of new and inexperienced directors

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$0.56 loss per share (vs US$0.34 loss in 2Q 2021)

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.82 loss in 1Q 2021)

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

High number of new and inexperienced directors

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new and inexperienced directors

Adicet Bio Announces Positive Interim Clinical Data from First-Ever Allogeneic, Off-The-Shelf, Gamma Delta Car T Investigational Cell Therapy

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$2.84 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.48 loss in 2Q 2020)

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 3000E Growth Index

Senior VP, Chief Scientific & Operating Officer Stewart Abbot has left the company

Adicet Bio, Inc., Annual General Meeting, Apr 27, 2021

Revenue beats expectations

Full year 2020 earnings released: US$5.01 loss per share (vs US$1.63 loss in FY 2019)

Adicet Bio, Inc. Announces Initiation of its First-In-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Adicet Bio, Inc. Announces Board Changes

Director has left the company

Adicet Bio, Inc. Announces Resignation of Lloyd Klickstein as Chief Innovation Officer

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Adicet Bio, Inc. Résumé des fondamentaux

0.0x